Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
June 03, 2011
Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- New Alzheimer's Guidelines Call for Use of Protein Biomarkers in Clinical Research
April 22, 2011 / ProteoMonitor - AD Working Group Proposes New Alzheimer's Definition to Include Protein Biomarkers
October 15, 2010 / ProteoMonitor - Initial Analysis of ADNI Plasma Proteome Data Suggests Possible Protein Signatures for Alzheimer's
December 10, 2010 / ProteoMonitor - BSI Partnering with Pharnext on $14.2M Initiative to Develop Biomarkers and Therapeutics for AD
November 19, 2010 / ProteoMonitor - TARC Team Uses RBM's DiscoveryMAP Platform to Develop Alzheimer's Protein-Biomarker Test
September 17, 2010 / ProteoMonitor